Third-Line Treatment Options for Kidney Cancer

Oncology (Williston Park). 2016 Sep 15;30(9):813-5.
No abstract available

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / genetics
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / genetics
  • Carcinoma, Renal Cell / mortality
  • Carcinoma, Renal Cell / pathology
  • Cost-Benefit Analysis
  • Drug Costs
  • Drug Substitution*
  • Genetic Predisposition to Disease
  • Genetic Testing / methods
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / genetics
  • Kidney Neoplasms / mortality
  • Kidney Neoplasms / pathology
  • Patient Selection
  • Phenotype
  • Precision Medicine
  • Predictive Value of Tests
  • Time Factors
  • Treatment Failure

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor